Arrowhead Pharmaceuticals, Inc.
ARWR
$21.33
$0.582.80%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.60% | 395.65% | -30.27% | -55.49% | -65.91% |
| Total Depreciation and Amortization | 30.13% | 34.45% | 22.80% | 30.22% | 45.97% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 24.31% | 51.81% | 34.13% | -3.68% | 12.93% |
| Change in Net Operating Assets | -172.88% | 1,251.69% | 31.57% | -86.47% | -55.93% |
| Cash from Operations | -34.05% | 598.02% | -24.13% | -429.26% | -455.51% |
| Capital Expenditure | 83.64% | 84.45% | 89.05% | 61.99% | 69.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 571.81% | -76.66% | -36.76% | -310.38% | -41.69% |
| Cash from Investing | 1,934.68% | -56.25% | 18.62% | -830.68% | 170.16% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -42.38% | -43.36% | 137.45% | -72.84% | -65.93% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -- | -- | -- | -- |
| Cash from Financing | -184.70% | -78.55% | 7,628.09% | 47,292.08% | 4,335.48% |
| Foreign Exchange rate Adjustments | 141.70% | -1,646.15% | -217.24% | 2,733.99% | -182.28% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4.10% | 89.70% | 7.37% | 498.99% | -96.81% |